<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263808</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149B2339</org_study_id>
    <nct_id>NCT01263808</nct_id>
  </id_info>
  <brief_title>Cardiac Safety of Indacaterol</brief_title>
  <official_title>A Randomized, Multiple-dose, Placebo- and Positive-controlled Parallel Group Study to Evaluate the Effects of Indacaterol on Cardiac Safety in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral
      moxifloxacin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QTc interval (Fridericia's)</measure>
    <time_frame>Change from baseline (prior to the first dose) to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in uncorrected QT interval</measure>
    <time_frame>Change from baseline (prior to the first dose) to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Indacaterol 150 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 150 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indacaterol 300 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 300 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indacaterol 600 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 600 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo/moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol 150 µg</intervention_name>
    <description>Once daily (QD) via single-dose dry powder inhaler (SDDPI)</description>
    <arm_group_label>Indacaterol 150 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol 300 µg</intervention_name>
    <description>QD via SDDPI</description>
    <arm_group_label>Indacaterol 300 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol 600 µg</intervention_name>
    <description>QD via SDDPI</description>
    <arm_group_label>Indacaterol 600 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>QD via SDDPI</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/moxifloxacin</intervention_name>
    <description>Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg</description>
    <arm_group_label>Placebo/moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking

          -  Body mass index (BMI) 18.5-32 kg/m2

          -  Body weight at least 50 kg

        Exclusion Criteria:

          -  Recent/concurrent use of concomitant medications (except acetaminophen)

          -  Recent participation in other clinical trials

          -  Recent donation or loss of blood

          -  History/presence of a range of medical conditions, including electrocardiographic
             (ECG) abnormalities, diabetes mellitus, hyperthyroidism and impaired renal function

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>December 20, 2010</last_update_submitted>
  <last_update_submitted_qc>December 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Indacaterol</keyword>
  <keyword>Moxifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

